These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27418644)

  • 21. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.
    Shinoda K; Sugiyama E; Taki H; Harada S; Mino T; Maruyama M; Kobayashi M
    Bone; 2003 Oct; 33(4):711-20. PubMed ID: 14555277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
    de Haart SJ; van de Donk NW; Minnema MC; Huang JH; Aarts-Riemens T; Bovenschen N; Yuan H; Groen RW; McMillin DW; Jakubikova J; Lokhorst HM; Martens AC; Mitsiades CS; Mutis T
    Clin Cancer Res; 2013 Oct; 19(20):5591-601. PubMed ID: 24004671
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
    Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
    Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-γ and CD40 ligand in vitro.
    Li H; Lu Y; Qian J; Zheng Y; Zhang M; Bi E; He J; Liu Z; Xu J; Gao JY; Yi Q
    J Bone Miner Res; 2014 Dec; 29(12):2666-75. PubMed ID: 24916315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
    Tamura H; Ishibashi M; Yamashita T; Tanosaki S; Okuyama N; Kondo A; Hyodo H; Shinya E; Takahashi H; Dong H; Tamada K; Chen L; Dan K; Ogata K
    Leukemia; 2013 Feb; 27(2):464-72. PubMed ID: 22828443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
    Chen H; Li M; Ng N; Yu E; Bujarski S; Yin Z; Wen M; Hekmati T; Field D; Wang J; Nassir I; Yu J; Huang J; Daniely D; Wang CS; Xu N; Spektor TM; Berenson JR
    Br J Haematol; 2021 Feb; 192(3):568-576. PubMed ID: 33341940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of CD4
    Zhang X; Gao L; Meng K; Han C; Li Q; Feng Z; Chen L
    Cell Immunol; 2018 May; 327():62-67. PubMed ID: 29454645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.
    Zhang J; Liu Z; Cao P; Wang H; Liu H; Hua L; Xue H; Fu R
    Cancer Med; 2022 Dec; 11(24):4838-4848. PubMed ID: 35593325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
    Ray A; Song Y; Du T; Chauhan D; Anderson KC
    Oncogene; 2020 Mar; 39(13):2786-2796. PubMed ID: 32024967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 39. DC-STAMP Is an Osteoclast Fusogen Engaged in Periodontal Bone Resorption.
    Wisitrasameewong W; Kajiya M; Movila A; Rittling S; Ishii T; Suzuki M; Matsuda S; Mazda Y; Torruella MR; Azuma MM; Egashira K; Freire MO; Sasaki H; Wang CY; Han X; Taubman MA; Kawai T
    J Dent Res; 2017 Jun; 96(6):685-693. PubMed ID: 28199142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.